Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
61 Results for "
N-Ras
" in MedChemExpress (MCE) Product Catalog:
Products (61)
61 Results for "N-Ras" in MCE Product Catalog:
Cat. No.: HY-116428
CAS No.: 160141-09-3
Research Areas:
L-744832 is a farnesyl transferase inhibitor. L-744832 effectively inhibits the farnesylation of H-Ras and N-Ras, but has little effect on K-Ras treatment. L-744832 not only directly targets the oncogenic pathway by inhibiting Ras farnesylation, but also enhances radiosensitivity by restoring TGF-β signaling through epigenetic reprogramming. L-744832 can induce cell cycle arrest and apoptosis. L-744832 can be used in combination therapy studies for Ras-driven tumors such as pancreatic cancer .
Cat. No.: HY-RS09559
Target:
Research Areas:
Nras Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nras gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS09558
Target:
Research Areas:
NRAS Human Pre-designed siRNA Set A contains three designed siRNAs for NRAS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-163515
Anticancer agent 207 (compound 10b) is a potent anticancer agent. Anticancer agent 207 bounds to the NRAS rG4 with a KD value of 2.31 µM. Anticancer agent 207 shows cytotoxicity and decreases the expression of NRAS protein. Anticancer agent 207 shows antitumor activity .
Cat. No.: HY-162536
Target:
Research Areas:
Pan-RAS-IN-5 is a macrocyclic pan-RAS inhibitor that targets mutant RAS (including KRAS, NRAS, and HRAS). Pan-RAS-IN-5 inhibits the proliferation of various KRAS-mutant cancer cells. Pan-RAS-IN-5 is applicable to the research of KRAS mutation-related cancers such as pancreatic cancer, nephroblastoma, and colon adenocarcinoma .
Cat. No.: HY-W1126467
CAS No.: 3061844-70-7
RAS-IN-5 (Example 2) is a RAS inhibitor. RAS-IN-5 significantly inhibits the interaction between RAF1 and active KRAS mutant protein or HRAS WT protein. RAS-IN-5 significantly inhibits the cell viability of KRAS, NRAS, and EGFR mutant cells. RAS-IN-5 can be used in the research of colorectal cancer, liver cancer, and non-small cell lung cancer .
Cat. No.: HY-176343S
Cat. No.: HY-P73741A
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: NRas; Proto-Oncogene GTPase; NRas Proto-Oncogene, GTPase; N-Ras Protein Part 4; N-Ras; ALPS4; Neuroblastoma Ras Viral (V-Ras) Oncogene Homolog; NRas1; Neuroblastoma Ras Viral Oncogene Homolog; HRas1; Transforming Protein N-Ras; CMNS; GTPase NRas; NCMS; V-
Species:
Human
Source:
E. coli
Cat. No.: HY-P73741
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NRas; Proto-Oncogene GTPase; NRas Proto-Oncogene, GTPase; N-Ras Protein Part 4; N-Ras; ALPS4; Neuroblastoma Ras Viral (V-Ras) Oncogene Homolog; NRas1; Neuroblastoma Ras Viral Oncogene Homolog; HRas1; Transforming Protein N-Ras; CMNS; GTPase NRas; NCMS; V-
Species:
Human
Source:
E. coli
Cat. No.: HY-RS09560
Target:
Research Areas:
Nras Rat Pre-designed siRNA Set A contains three designed siRNAs for Nras gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-149705
CAS No.: 1313603-21-2
ICMT-IN-7 (compound 74) is an inhibitor of ICMT (IC50=0.015 μM). ICMT-IN-7 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .
Cat. No.: HY-101641
CAS No.: 204718-47-8
Research Areas:
NRA-0160 is a selective dopamine D4 receptor antagonist, with a Ki value of 0.48 nM and with negligible affinity for dopamine D2 receptor (Ki: >10000 nM), D3 receptor (Ki: 39 nM), rat 5-HT2A receptor (Ki: 180 nM) and rat α1 adrenoceptor (Ki: 237 nM).
Cat. No.: HY-108887
CAS No.: 1884226-20-3
Anticancer agent 124 is an orally active, highly selective and potent pan RAF inhibitor. Anticancer agent 124 inhibits MAPK signalling in BRAF V600E, NRAS and KRAS mutant tumor cells .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
